Halozyme Therapeutics (HALO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
146.8mn → 123.9mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
−34.8% YoY in FY25 · 0.5% of revenue.
$342.4M returned vs $644.6M of FCF in FY25. Buybacks covered by cash flow.
23¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 81.6% → 83.6%. Net margin 22.7% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,802.4 | 1,396.6 | 1,015.3 | 829.3 | 660.1 | 443.3 | ▲37.6% | +33.2% |
Cost of revenue | 319.7 | 228.8 | 159.4 | 192.4 | 139.3 | 81.4 | ▲43.5% | +29.5% |
Gross profit | 1,482.8 | 1,167.8 | 855.9 | 636.9 | 520.8 | 361.9 | ▲36.4% | +34.0% |
Research & development | 397.8 | 366.4 | 79.0 | 76.4 | 66.6 | 35.7 | ▲363.5% | +79.0% |
Selling, general & admin | 250.1 | 207.1 | 154.3 | 149.2 | 143.5 | 50.3 | ▲34.2% | +42.4% |
Total operating expenses | 808.5 | 698.8 | 304.4 | 299.3 | 253.3 | 86.0 | ▲129.6% | +68.8% |
Operating incomefeeds ROC rank | 674.2 | 469.0 | 551.5 | 337.6 | 267.5 | 275.9 | ▼15.0% | +14.2% |
Other income, net | −19.2 | −2.1 | 5.7 | 10.8 | −18.6 | −27.4 | — | — |
Pretax income | 655.0 | 466.9 | 557.1 | 348.3 | 248.9 | 248.5 | ▼16.2% | +17.1% |
Income tax | 169.6 | 150.0 | 113.0 | 66.7 | 46.8 | −154.2 | ▲32.7% | +47.4% (22→25) |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 485.4 | 316.9 | 444.1 | 281.6 | 202.1 | 402.7 | ▼28.6% | −5.8% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 4.00 | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 | ▼25.4% | −1.7% |
Diluted shares (mn) | 122.61 | 123.90 | 129.42 | 134.20 | 140.61 | 146.80 | ▼4.3% | −4.1% |
| Margins | ||||||||
Gross margin76th pct in Healthcare | 82.3% | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | ▼0.7pp | +2.0pp |
Operating margin | 37.4% | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% | ▼20.7pp | −28.7pp |
Net margin92nd pct in Healthcare | 26.9% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | ▼21.0pp | −68.2pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Halozyme Therapeutics' revenue last fiscal year?
Halozyme Therapeutics reported revenue of $1,396.6M in fiscal 2025, up 37.6% from fiscal 2024.
What was Halozyme Therapeutics' net income?
Halozyme Therapeutics reported net income of $316.9M in fiscal 2025, a net margin of 22.7%.

